Literature DB >> 1676673

Oncogenic forms of the neu/HER2 tyrosine kinase are permanently coupled to phospholipase C gamma.

E Peles1, R B Levy, E Or, A Ullrich, Y Yarden.   

Abstract

The neu/HER2 proto-oncogene encodes a transmembrane tyrosine kinase homologous to receptors for polypeptide growth factors. The oncogenic potential for the presumed receptor is released through multiple genetic mechanisms including a specific point mutation, truncation at the extracellular domain and overexpression of the protooncogene. Here we show that all these modes of oncogenic activation result in a constitutively phosphorylated neu protein and an increase in tyrosine phosphorylation of a phosphatidylinositol-specific phospholipase (PLC gamma). The examined transforming neu/HER2 proteins, unlike the normal gene product, also co-immunoprecipitated with PLC gamma molecules. A kinase-defective mutant of a transforming neu failed to mediate both tyrosine phosphorylation and association with PLC gamma, suggesting direct interaction of the neu kinase with PLC gamma. This possibility was examined by employing a chimeric protein composed of the extracellular ligand-binding domain of the epidermal growth factor receptor and the neu cytoplasmic portion. The chimeric receptor mediated rapid ligand-dependent modification of PLC gamma on tyrosine residues. It also physically associated, in a ligand-dependent manner, with the phosphoinositidase. Based on the presented results we suggest that the mechanism of cellular transformation by the neu/HER2 receptor involves tyrosine phosphorylation and activation of PLC gamma.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1676673      PMCID: PMC452891          DOI: 10.1002/j.1460-2075.1991.tb07739.x

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  58 in total

1.  A new technique for the assay of infectivity of human adenovirus 5 DNA.

Authors:  F L Graham; A J van der Eb
Journal:  Virology       Date:  1973-04       Impact factor: 3.616

2.  Increased tyrosine kinase activity associated with the protein encoded by the activated neu oncogene.

Authors:  C I Bargmann; R A Weinberg
Journal:  Proc Natl Acad Sci U S A       Date:  1988-08       Impact factor: 11.205

3.  Biochemical analysis of the ligand for the neu oncogenic receptor.

Authors:  Y Yarden; E Peles
Journal:  Biochemistry       Date:  1991-04-09       Impact factor: 3.162

Review 4.  Studies of inositol phospholipid-specific phospholipase C.

Authors:  S G Rhee; P G Suh; S H Ryu; S Y Lee
Journal:  Science       Date:  1989-05-05       Impact factor: 47.728

5.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

Authors:  D J Slamon; G M Clark; S G Wong; W J Levin; A Ullrich; W L McGuire
Journal:  Science       Date:  1987-01-09       Impact factor: 47.728

6.  Heterodimerization of the erbB-1 and erbB-2 receptors in human breast carcinoma cells: a mechanism for receptor transregulation.

Authors:  R Goldman; R B Levy; E Peles; Y Yarden
Journal:  Biochemistry       Date:  1990-12-18       Impact factor: 3.162

7.  Antiphosphotyrosine recovery of phospholipase C activity after EGF treatment of A-431 cells.

Authors:  M I Wahl; T O Daniel; G Carpenter
Journal:  Science       Date:  1988-08-19       Impact factor: 47.728

8.  p185, a product of the neu proto-oncogene, is a receptorlike protein associated with tyrosine kinase activity.

Authors:  D F Stern; P A Heffernan; R A Weinberg
Journal:  Mol Cell Biol       Date:  1986-05       Impact factor: 4.272

9.  Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms.

Authors:  M H Kraus; N C Popescu; S C Amsbaugh; C R King
Journal:  EMBO J       Date:  1987-03       Impact factor: 11.598

10.  Oncogenic activation of the neu-encoded receptor protein by point mutation and deletion.

Authors:  C I Bargmann; R A Weinberg
Journal:  EMBO J       Date:  1988-07       Impact factor: 11.598

View more
  27 in total

1.  Inactivation of smad-transforming growth factor beta signaling by Ca(2+)-calmodulin-dependent protein kinase II.

Authors:  S J Wicks; S Lui; N Abdel-Wahab; R M Mason; A Chantry
Journal:  Mol Cell Biol       Date:  2000-11       Impact factor: 4.272

2.  Interkinase domain of kit contains the binding site for phosphatidylinositol 3' kinase.

Authors:  S Lev; D Givol; Y Yarden
Journal:  Proc Natl Acad Sci U S A       Date:  1992-01-15       Impact factor: 11.205

3.  Specific epidermal growth factor receptor autophosphorylation sites promote mouse colon epithelial cell chemotaxis and restitution.

Authors:  Toshimitsu Yamaoka; Mark R Frey; Rebecca S Dise; Jessica K Bernard; D Brent Polk
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2011-05-26       Impact factor: 4.052

Review 4.  SH2 domain-containing signaling proteins in human breast cancer.

Authors:  R J Daly
Journal:  Breast Cancer Res Treat       Date:  1995-04       Impact factor: 4.872

5.  HER-2 signaling, acquisition of growth factor independence, and regulation of biological networks associated with cell transformation.

Authors:  Aliccia Bollig-Fischer; Michele Dziubinski; Alaina Boyer; Ramsi Haddad; Craig N Giroux; Stephen P Ethier
Journal:  Cancer Res       Date:  2010-08-24       Impact factor: 12.701

6.  Interspecies molecular chimeras of kit help define the binding site of the stem cell factor.

Authors:  S Lev; J Blechman; S Nishikawa; D Givol; Y Yarden
Journal:  Mol Cell Biol       Date:  1993-04       Impact factor: 4.272

7.  A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor.

Authors:  E Tzahar; H Waterman; X Chen; G Levkowitz; D Karunagaran; S Lavi; B J Ratzkin; Y Yarden
Journal:  Mol Cell Biol       Date:  1996-10       Impact factor: 4.272

8.  Neural expression and chromosomal mapping of Neu differentiation factor to 8p12-p21.

Authors:  A Orr-Urtreger; L Trakhtenbrot; R Ben-Levy; D Wen; G Rechavi; P Lonai; Y Yarden
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-01       Impact factor: 11.205

9.  Heterodimerization of epidermal growth factor receptor and wild-type or kinase-deficient Neu: a mechanism of interreceptor kinase activation and transphosphorylation.

Authors:  X Qian; C M LeVea; J K Freeman; W C Dougall; M I Greene
Journal:  Proc Natl Acad Sci U S A       Date:  1994-02-15       Impact factor: 11.205

10.  LMO4 is an essential mediator of ErbB2/HER2/Neu-induced breast cancer cell cycle progression.

Authors:  M E Montañez-Wiscovich; D D Seachrist; M D Landis; J Visvader; B Andersen; R A Keri
Journal:  Oncogene       Date:  2009-08-03       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.